Loading
After a lutetium-177 treatment your body gives off a small amount of radiation for some days, and most of the radioactivity leaves in your urine. For a short time you are asked to keep some distance from others, especially children and anyone pregnant, to sleep apart, to be careful with the toilet and washing, and to drink plenty. Your team will give you written instructions with the exact days.
Release follows national law: the EANM/SNMMI 2023 guideline notes that up to 48 to 72 hours of ward isolation may be needed to reach a local discharge threshold, and that where outpatient treatment is allowed the patient should stay about 2 hours to be monitored, hydrated and to pass urine first. In the United States 10 CFR 35.75 allows release where no other person is likely to receive more than 5 mSv, with written instructions where anyone could receive more than 1 mSv. Precautions: drink more for 3 to 4 days and void often (EANM/SNMMI; both US labels); rigorous toilet hygiene, a double flush and hand washing, with particular care in the first 2 days and against soiling for a week (IAEA/EANM/SNMMI 2013 for PRRT); catheterise incontinent patients and keep the catheter for 2 days (IAEA 2013), and EANM/SNMMI suggests considering a catheter. The Pluvicto label gives the most specific contact limits after each dose: under 3 feet from others for 2 days and from children and pregnant women for 7 days, no sexual activity for 7 days, and separate sleeping for 3, 7 and 15 days (others, children, pregnant women). The Lutathera label gives no day counts and notes radioactivity in urine for up to 30 days. Contraception figures differ by source: Pluvicto men 14 weeks after the last dose; Lutathera women 7 months and men 4 months, no breastfeeding for 2.5 months; EANM/SNMMI 3 months for PSMA; IAEA 2013 at least 6 months avoiding pregnancy for women after PRRT. A medical emergency is never delayed for radiation reasons.
Why: The rules on when someone can go home after a radioactive treatment differ between countries; the short stay also lets the team check side effects and that the patient can pass urine.
“Where out-patient therapy is allowed, patients should nevertheless be kept in isolation for approx. 2 h to monitor side effects, ensure sufficient hydration, and complete first urination before release.”
EANM and SNMMI (European Journal of Nuclear Medicine and Molecular Imaging; Kratochwil et al.) 2023
Why: People remember little of what is said on treatment day; a written sheet with the dates lets the household follow it.
“A licensee shall provide the released individual, or the individual's parent or guardian, with instructions, including written instructions, on actions recommended to maintain doses to other individuals as low as is reasonably achievable if the total effective dose equivalent to any other individual is likely to exceed 1 mSv (0.1 rem).”
US Nuclear Regulatory Commission (Electronic Code of Federal Regulations) 2007
Why: Most of the radioactivity leaves in urine; drinking and emptying the bladder often clears it faster and lowers the dose to the bladder and kidneys.
“To support kidney clearance, the patient is encouraged to increase fluid intake during the first 3–4 days following treatment.”
EANM and SNMMI (European Journal of Nuclear Medicine and Molecular Imaging; Kratochwil et al.) 2023
Why: Urine is the main source of contamination in the home for the first days, and others may use the same toilet.
“Patients should be advised to observe rigorous hygiene to avoid contaminating persons using the same toilet facilities. A double toilet flush is recommended after urination. Patients should wash their hands after urination.”
IAEA, EANM and SNMMI (European Journal of Nuclear Medicine and Molecular Imaging) 2013
Why: Small amounts of radioactive urine on clothes or surfaces are the commonest way others are exposed.
“Once discharged, patients should be cautioned to avoid soiling underclothing or areas around toilet bowls for 1 week following PRRNT. Considerably contaminated clothing should be washed separately.”
IAEA, EANM and SNMMI (European Journal of Nuclear Medicine and Molecular Imaging) 2013
Why: A catheter keeps radioactive urine contained when the bladder cannot be controlled.
“Incontinent patients should be catheterized prior to PRRNT and the catheter should be kept for 2 days thereafter.”
IAEA, EANM and SNMMI (European Journal of Nuclear Medicine and Molecular Imaging) 2013
Why: The treatment gives off some gamma radiation for several days, and distance cuts the dose to others sharply; children and unborn babies are more sensitive.
“Limit close contact (less than 3 feet) with others for 2 days or with children and pregnant women for 7 days.”
Novartis, via DailyMed (US National Library of Medicine) 2026
Why: Hours spent close together at night account for much of a partner's dose.
“Sleep in a separate room from others for 3 days, from children for 7 days, or from pregnant women for 15 days.”
Novartis, via DailyMed (US National Library of Medicine) 2026
Why: Radiation can harm an unborn baby and sperm and eggs; the advised gap differs between the drugs and the guidelines.
“Advise females of reproductive potential to use effective contraception during treatment with LUTATHERA and for 7 months after the last dose.”
Advanced Accelerator Applications, via DailyMed (US National Library of Medicine) 2026
Why: Other clinicians need to know what was given, and urine can carry detectable radioactivity for weeks (up to 30 days after Lutathera, by its US label).
“The discharge letter should contain relevant patient data, date of therapy, the administered radionuclide (177Lu) and radiopharmaceutical, administered activity, details on necessary aftercare, and next follow-up appointment.”
EANM and SNMMI (European Journal of Nuclear Medicine and Molecular Imaging; Kratochwil et al.) 2023
Why: The dose to staff from a treated patient is small compared with the harm of delayed treatment.
“In a medical emergency, concerns about radiation exposure should not hinder the prompt delivery of appropriate medical care to the patient.”
IAEA, EANM and SNMMI (European Journal of Nuclear Medicine and Molecular Imaging) 2013
How care is usually carried out, read from the guidelines and standards cited. Your own team's protocol and their judgement come first; this page is for understanding it, not for doing it yourself.
Release under national rules (EANM/SNMMI 2023: up to 48 to 72 hours' isolation where the law requires it, otherwise about 2 hours' observation; US 10 CFR 35.75: release where no one else is likely to receive more than 5 mSv, with written instructions above 1 mSv), followed by written home precautions: plenty to drink and frequent voiding, rigorous toilet hygiene with a double flush and hand washing (IAEA/EANM/SNMMI 2013), catheterisation for incontinence, distance and separate sleeping for set periods (the US Pluvicto label is the most specific: 2 and 7 days of limited close contact, 3, 7 and 15 days of separate sleeping, 7 days without sexual activity), and contraception. The sources disagree on contraception after treatment: for Lutathera, 7 months for women and 4 months for men (US label) against at least 6 months avoiding pregnancy (IAEA 2013); for PSMA, 14 weeks for men (US label) against 3 months (EANM/SNMMI). Patients should follow the figure their own team gives, which is set by the product licence in their country.
EANM and SNMMI (European Journal of Nuclear Medicine and Molecular Imaging; Kratochwil et al.) 2023 · IAEA, EANM and SNMMI (European Journal of Nuclear Medicine and Molecular Imaging) 2013 · Novartis, via DailyMed (US National Library of Medicine) 2026 · Advanced Accelerator Applications, via DailyMed (US National Library of Medicine) 2026 · US Nuclear Regulatory Commission (Electronic Code of Federal Regulations) 2007
Where it differs: Keeps the patient on a shielded radioisotope ward for up to 48 to 72 hours rather than treating as an outpatient.
Evidence: Set by national law rather than by evidence about outcomes: EANM/SNMMI 2023 says that, depending on national legislation, up to 48 to 72 hours of isolation on a radioisotope ward may be needed to reach the local discharge threshold. The United States allows outpatient release under the 5 mSv rule.
EANM and SNMMI (European Journal of Nuclear Medicine and Molecular Imaging; Kratochwil et al.) 2023 · US Nuclear Regulatory Commission (Electronic Code of Federal Regulations) 2007
Where it differs: Pluvicto (US label): men with female partners, 14 weeks after the last dose. Lutathera (US label): women 7 months, men 4 months, and no breastfeeding for 2.5 months. EANM/SNMMI (PSMA): 3 months. IAEA/EANM/SNMMI (PRRT, 2013): women to avoid pregnancy for at least 6 months, and men to consider sperm banking before therapy.
Evidence: No trial compares them; the label periods derive from the drug's half-life and genotoxicity, and EANM/SNMMI states its 3 months is "Without specific evidence for 177Lu-PSMA-RLT, but according to general knowledge of radiopharmaceuticals".
Novartis, via DailyMed (US National Library of Medicine) 2026 · Advanced Accelerator Applications, via DailyMed (US National Library of Medicine) 2026 · EANM and SNMMI (European Journal of Nuclear Medicine and Molecular Imaging; Kratochwil et al.) 2023 · IAEA, EANM and SNMMI (European Journal of Nuclear Medicine and Molecular Imaging) 2013
After lutetium-177 treatment for prostate cancer or neuroendocrine tumours, patients are told how long to avoid pregnancy or breastfeeding, but the numbers differ by source: 3 months, 14 weeks, 4 months, 6 months or 7 months. A single table, with the reasoning for each figure, would let teams and families give the same answer.
| Recommendation | Grade, as printed | Source |
|---|---|---|
| Release where no other person is likely to receive more than 5 mSv “if the total effective dose equivalent to any other individual from exposure to the released individual is not likely to exceed 5 mSv (0.5 rem).” | US federal regulation (10 CFR 35.75(a)) | US Nuclear Regulatory Commission (Electronic Code of Federal Regulations) 2007 |
| Instruct patients how to minimise exposure to others, such as avoiding prolonged close contact with pregnant women or infants “Patients should be instructed how to minimize exposure to others (e.g., avoiding prolonged close contact with pregnant women or infants).” | Procedure guideline statement (not graded) | EANM and SNMMI (European Journal of Nuclear Medicine and Molecular Imaging; Kratochwil et al.) 2023 |
| Contraception during and for 3 months after lutetium-177 PSMA therapy “Due to the pro-mutagenic characteristics of any radioactive drug, sufficient contraception is needed during and for 3 months after therapy.” | Procedure guideline statement, stated to be without specific evidence | EANM and SNMMI (European Journal of Nuclear Medicine and Molecular Imaging; Kratochwil et al.) 2023 |
| Contraception for men after Pluvicto, 14 weeks after the last dose “Advise males with female partners of reproductive potential to use effective contraception during treatment with PLUVICTO and for 14 weeks after the last dose” | US prescribing information (FDA label) | Novartis, via DailyMed (US National Library of Medicine) 2026 |
| No breastfeeding during Lutathera and for 2.5 months after the last dose “Because of the potential risk for serious adverse reactions in breastfed children, advise women not to breastfeed during treatment with LUTATHERA and for 2.5 months after the last dose.” | US prescribing information (FDA label) | Advanced Accelerator Applications, via DailyMed (US National Library of Medicine) 2026 |
| Radioactivity in urine for up to 30 days after Lutathera “Radiation can be detected in the urine for up to 30 days following LUTATHERA administration.” | US prescribing information (FDA label) | Advanced Accelerator Applications, via DailyMed (US National Library of Medicine) 2026 |
Shares Lutetium-177 dotatate, Lutetium-177 vipivotide tetraxetan, Neuroendocrine tumours, Prostate cancer.
Shares Lutetium-177 radioligand therapy, Neuroendocrine tumours, Prostate cancer.
Shares One aligned table of contraception and breastfeeding intervals after lutetium-177 therapy.
Shares Lutetium-177 dotatate, Lutetium-177 vipivotide tetraxetan, Neuroendocrine tumours, Prostate cancer.
Shares Lutetium-177 dotatate, Lutetium-177 vipivotide tetraxetan, Neuroendocrine tumours, Prostate cancer.
Shares Lutetium-177 dotatate, Lutetium-177 vipivotide tetraxetan, Neuroendocrine tumours, Prostate cancer.